These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
302 related items for PubMed ID: 17825459
1. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Vaccine; 2007 Oct 10; 25(41):7041-6. PubMed ID: 17825459 [Abstract] [Full Text] [Related]
2. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Rezapkin G, Martin J, Chumakov K. Biologicals; 2005 Mar 10; 33(1):29-39. PubMed ID: 15713554 [Abstract] [Full Text] [Related]
3. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains. Sawyer LA, McInnis J, Albrecht P. Biologicals; 1993 Jun 10; 21(2):169-77. PubMed ID: 8297601 [Abstract] [Full Text] [Related]
4. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM. J Infect Dis; 2004 Oct 15; 190(8):1404-12. PubMed ID: 15378432 [Abstract] [Full Text] [Related]
5. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. Crawt L, Atkinson E, Tedcastle A, Pegg E, sIPV Study Group, Minor P, Cooper G, Rigsby P, Martin J. J Infect Dis; 2020 Feb 03; 221(4):544-552. PubMed ID: 30788503 [Abstract] [Full Text] [Related]
6. Mapping of type 1 poliovirus neutralization epitopes. Blondel B, Crainic R, Dufraisse G, Candréa A, Horaud F. Dev Biol Stand; 1985 Feb 03; 60():337-42. PubMed ID: 2412917 [Abstract] [Full Text] [Related]
7. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site. Sawyer LA, Wood D, Ferguson M, Crainic R, Beuvery EC, McInnis J, Albrecht P. Biologicals; 1997 Sep 03; 25(3):299-306. PubMed ID: 9324998 [Abstract] [Full Text] [Related]
8. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Kersten G, Hazendonk T, Beuvery C. Vaccine; 1999 Apr 09; 17(15-16):2059-66. PubMed ID: 10217607 [Abstract] [Full Text] [Related]
9. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine. Dragunsky EM, Ivanov AP, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM. J Infect Dis; 2006 Sep 15; 194(6):804-7. PubMed ID: 16941347 [Abstract] [Full Text] [Related]
10. Intratypic differentiation of poliovirus strains by enzyme-linked immunosorbent assay (ELISA): poliovirus type 1. Glikmann G, Moynihan M, Petersen I, Vestergaard BF. Dev Biol Stand; 1983 Sep 15; 55():199-208. PubMed ID: 6203794 [Abstract] [Full Text] [Related]
11. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada. Wachmann B, Henning D, Armstrong R, Boucher DW, Contreras G, Furesz J. Dev Biol Stand; 1984 Sep 15; 57():141-9. PubMed ID: 6084605 [Abstract] [Full Text] [Related]
12. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D. Vaccine; 2015 Nov 27; 33(48):6611-6. PubMed ID: 26529068 [Abstract] [Full Text] [Related]
13. Development of inactivated poliovirus vaccine derived from Sabin strains. Simizu B, Abe S, Yamamoto H, Tano Y, Ota Y, Miyazawa M, Horie H, Satoh K, Wakabayashi K. Biologicals; 2006 Jun 27; 34(2):151-4. PubMed ID: 16679028 [Abstract] [Full Text] [Related]
14. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Doi Y, Abe S, Yamamoto H, Horie H, Ohyama H, Satoh K, Tano Y, Ota Y, Miyazawa M, Wakabayashi K, Hashizume S. Dev Biol (Basel); 2001 Jun 27; 105():163-9. PubMed ID: 11763324 [Abstract] [Full Text] [Related]
15. Antigenic structure of poliovirus in inactivated vaccines. Ferguson M, Wood DJ, Minor PD. J Gen Virol; 1993 Apr 27; 74 ( Pt 4)():685-90. PubMed ID: 7682250 [Abstract] [Full Text] [Related]
16. Neutralization epitope patterns of poliovirus strains isolated from paralytic cases. Crainic R, Blondel B, Aubert-Combiescu A, Beytout D, Couillin P, Candrea A, Boué A, Horaud F. Dev Biol Stand; 1984 Apr 27; 57():165-70. PubMed ID: 6084607 [Abstract] [Full Text] [Related]
17. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures. Crainic R, Blondel B, Candréa A, Dufraisse G, Horaud F. Dev Biol Stand; 1985 Apr 27; 60():343-7. PubMed ID: 2995173 [Abstract] [Full Text] [Related]
18. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA. Vaccine; 2013 Nov 12; 31(47):5531-6. PubMed ID: 24063976 [Abstract] [Full Text] [Related]
19. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice. Buttinelli G, Ruggeri FM, Marturano J, Novello F, Donati V, Fiore L. Virology; 2001 Mar 15; 281(2):265-71. PubMed ID: 11277698 [Abstract] [Full Text] [Related]